[go: up one dir, main page]

PE20050307A1 - 2- (BUTIL-1-SULFONYLAMINO) -N- [1 (R) - (6-METOXIPIRIDIN-3-IL) PROPYL] BENZAMIDE, ITS USE AS A MEDICINAL PRODUCT AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT - Google Patents

2- (BUTIL-1-SULFONYLAMINO) -N- [1 (R) - (6-METOXIPIRIDIN-3-IL) PROPYL] BENZAMIDE, ITS USE AS A MEDICINAL PRODUCT AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT

Info

Publication number
PE20050307A1
PE20050307A1 PE2004000245A PE2004000245A PE20050307A1 PE 20050307 A1 PE20050307 A1 PE 20050307A1 PE 2004000245 A PE2004000245 A PE 2004000245A PE 2004000245 A PE2004000245 A PE 2004000245A PE 20050307 A1 PE20050307 A1 PE 20050307A1
Authority
PE
Peru
Prior art keywords
benzamide
propyl
metoxipiridin
butil
sulfonylamino
Prior art date
Application number
PE2004000245A
Other languages
Spanish (es)
Inventor
Joachim Brendel
Heinz Gogelein
Klaus Wirth
Gert Ulrich Kurzel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20050307A1 publication Critical patent/PE20050307A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A 2-(BUTIL-1-SULFONILAMINO)-N-[1(R)-(6-METOXIPIRIDIN-3-IL)PROPIL]-BENZAMIDA, INCLUYENDO SUS SALES FISIOLOGICAMENTE TOLERABLES Y EL USO DE ESTE COMPUESTO COMO UN MEDICAMENTO PARA LA TERAPIA O PROFILAXIS DE ARRITMIAS CARDIACAS, ARRITMIAS SUPRAVENTRICULARES, FIBRILACION AURICULAR Y/O ALETEOS AURICULARES. TAMBIEN SE REFIERE AL USO DEL COMPUESTO 1(R)-(6-METOXIPIRIDIN-3-IL)PROPILAMINA COMO INTERMEDIARIO PARA LA PREPARACION DEL COMPUESTO 2-(BUTIL-1-SULFONILAMINO)-N-[1(R)-(6-METOXIPIRIDIN-3-IL)PROPIL]-BENZAMIDAREFERS TO 2- (BUTYL-1-SULFONYLAMINE) -N- [1 (R) - (6-METHOXYPIRIDIN-3-IL) PROPYL] -BENZAMIDE, INCLUDING ITS PHYSIOLOGICALLY TOLERABLE SALTS AND THE USE OF THIS COMPOUND AS A MEDICINE FOR THE THERAPY OR PROPHYLAXIS OF CARDIAC ARRHYTHMIAS, SUPRAVENTRICULAR ARRHYTHMIAS, ATRIAL FIBRILLATION AND / OR ATRIAL FINS. IT ALSO REFERS TO THE USE OF THE COMPOUND 1 (R) - (6-METOXYPIRIDIN-3-IL) PROPYLAMINE AS AN INTERMEDIARY FOR THE PREPARATION OF THE COMPOUND 2- (BUTYL-1-SULFONYLAMINE) -N- [1 (R) - (6- METOXYPYRIDIN-3-IL) PROPYL] -BENZAMIDE

PE2004000245A 2003-03-18 2004-03-05 2- (BUTIL-1-SULFONYLAMINO) -N- [1 (R) - (6-METOXIPIRIDIN-3-IL) PROPYL] BENZAMIDE, ITS USE AS A MEDICINAL PRODUCT AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT PE20050307A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (en) 2003-03-18 2003-03-18 2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3yl) -propyl] -benzamide, its use as a medicament and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
PE20050307A1 true PE20050307A1 (en) 2005-06-08

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000245A PE20050307A1 (en) 2003-03-18 2004-03-05 2- (BUTIL-1-SULFONYLAMINO) -N- [1 (R) - (6-METOXIPIRIDIN-3-IL) PROPYL] BENZAMIDE, ITS USE AS A MEDICINAL PRODUCT AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT

Country Status (21)

Country Link
EP (1) EP1606237A1 (en)
JP (1) JP2006520343A (en)
KR (1) KR20050110681A (en)
CN (1) CN100361943C (en)
AR (1) AR043622A1 (en)
AU (1) AU2004222137A1 (en)
BR (1) BRPI0408441A (en)
CA (1) CA2519022A1 (en)
DE (1) DE10312073A1 (en)
HR (1) HRP20050815A2 (en)
MA (1) MA27749A1 (en)
MX (1) MXPA05009763A (en)
MY (1) MY176510A (en)
NO (1) NO20054472L (en)
NZ (1) NZ542476A (en)
PE (1) PE20050307A1 (en)
RS (1) RS20050690A (en)
RU (1) RU2333202C2 (en)
TW (1) TW200500342A (en)
WO (1) WO2004083157A1 (en)
ZA (1) ZA200506328B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (en) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Use of specific 2-substituted benzamides for treating and preventing cardiac insufficiency, especially where caused by diastolic dysfunction, act by inhibition of the Kv1.5 potassium channel
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (en) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
US9101616B2 (en) * 2009-05-29 2015-08-11 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE167473T1 (en) * 1990-08-20 1998-07-15 Eisai Co Ltd SULFONAMIDE DERIVATIVES
DE10121003A1 (en) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
ZA200506328B (en) 2006-04-26
AR043622A1 (en) 2005-08-03
CA2519022A1 (en) 2004-09-30
CN1756728A (en) 2006-04-05
DE10312073A1 (en) 2004-09-30
CN100361943C (en) 2008-01-16
RU2005132163A (en) 2006-04-10
NZ542476A (en) 2008-05-30
KR20050110681A (en) 2005-11-23
JP2006520343A (en) 2006-09-07
MY176510A (en) 2020-08-12
AU2004222137A1 (en) 2004-09-30
HK1086819A1 (en) 2006-09-29
MA27749A1 (en) 2006-02-01
RS20050690A (en) 2008-04-04
TW200500342A (en) 2005-01-01
BRPI0408441A (en) 2006-04-04
HRP20050815A2 (en) 2006-09-30
MXPA05009763A (en) 2006-01-27
RU2333202C2 (en) 2008-09-10
WO2004083157A1 (en) 2004-09-30
NO20054472L (en) 2005-09-27
EP1606237A1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
CU23105A3 (en) NOVEDOUS DERIVATIVES OF AMINODICARBOXILIC ACID WITH PHARMACEUTICAL PROPERTIES
CL2021001396A1 (en) Pantetheine derivatives and uses thereof
BR0214243A (en) Sulfonamide derivative Process for the preparation of a sulfonamide derivative and its physiologically acceptable salts, pharmaceutical composition and use of a sulfonamide derivative
LV12632A (en) Pyrazoline derivatives for their preparation and application as medicaments
BRPI0409109A (en) new compounds
PA8547701A1 (en) NUCLEOSIDS 4 SUBSTITUTED.
AR031430A1 (en) ORIS BISARILO COMPOUNDS, META-SUBSTITUTES, PROCEDURES FOR THEIR PREPARATION, ITS USE AS A MEDICINAL PRODUCT AS ALSO THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
BR0312729A (en) New indole-3-sulfur derivatives
EA200300776A1 (en) FENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
BR0210374A (en) Heteroarylsulfonyl side chain anthranilic acid amides, processes for producing them, use thereof as a medicine or diagnostic agent, as well as pharmaceutical preparations containing them
AR019853A1 (en) DERIVED FROM THE 3-ARIL-2-HYDROXIPROPIONIC ACID, PROCESS AND INTERMEDIARY FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS, USE OF SUCH COMPOUND IN THE PREPARATION OF A MEDICINAL PRODUCT, METHOD FOR THE PROPHYLAXIS AND / OR TREATMENT OF CLINIC ASSOCIATED RESISTANCES AND FORMULATION
HN2000000050A (en) MUTUAL SALT OF AMLODIPINO AND ATORVASTATINA
AR104068A1 (en) COMBINATIONS OF A 3-KINASE PHOSFOINOSYTIDE INHIBITOR COMPOSITE AND A CDK4 / 6 INHIBITOR COMPOUND FOR CANCER TREATMENT
AR039633A2 (en) USE OF A CABERGOLINE TYPE COMPOUND TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF FIBROMIALGIA AND THE CHRONIC FATIGUE SYNDROME
EA199700380A1 (en) BICYCLIC AROMATIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS ON THEIR BASIS AND APPLICATION OF COSMETIC COMPOSITIONS
AR033659A1 (en) THE COMPOUND 2- (3,5-BIS -TRIFLUORMETHYL-PHENYL) -N-METHYL-N- (6-MORFOLIN-4-IL-4-O-TOLIL-PIRIDIN-3-IL) -ISOBUTIRAMIDA), ITS USE, A PROCEDURE TO PREPARE IT AND A MEDICINAL PRODUCT CONTAINING IT
ES2163735T3 (en) HETEROCICLIC BIARILE COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT CONTAIN THEM AND USES.
AR073265A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF ICTUS OR TRANSITIONAL ISCHEMICAL ATTACK
HN2000000075A (en) AMLODIPINO AND ATORVASTATIN MUTUAL PROPHARMS
BRPI0410623A (en) compound, process for preparing a compound, pharmaceutical composition, and use of a compound
PE20050307A1 (en) 2- (BUTIL-1-SULFONYLAMINO) -N- [1 (R) - (6-METOXIPIRIDIN-3-IL) PROPYL] BENZAMIDE, ITS USE AS A MEDICINAL PRODUCT AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT
NO20062824L (en) 1,3-Diphenylprop-2-en-1-one derived compounds, processes for their preparation, and use of the same
ES2177671T3 (en) ENTERZINETIC BENZAMIDE.
AR037427A1 (en) QUINOLINE COMPOUND, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, PROCEDURE TO PREPARE IT AND UTILITY QUINOLINE COMPOUNDS AS INTERMEDIARIES IN THIS PROCEDURE
UY27910A1 (en) USE OF A SPECIFIC CYCLIC AMINE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS TO TREAT OR PREVENT CARDIAC INSUFFICIENCY

Legal Events

Date Code Title Description
FC Refusal